Diabetes research and clinical practiceJan 24, 2026

Heart failure with normal pumping strength: causes, diagnosis, and new treatment approaches

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 25, 2026

Abstract

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of global heart failure cases.

HFpEF is associated with significant symptom burden, frequent hospitalizations, and limited treatment options.
The condition involves complex interactions across vascular, heart muscle, metabolic, and inflammatory pathways, leading to diastolic dysfunction.
Diagnostic challenges include inconsistencies and the need for exertional testing to identify increased filling pressures.
Recent therapeutic advances include sodium glucose cotransporter-2 (SGLT2) inhibitors as foundational treatment and glucagon-like peptide-1 receptor agonists (GLP-1RAs) as potential adjunctive therapy.
HFpEF encompasses a range of endotypes characterized by diastolic dysfunction but driven by different systemic mechanisms, which may lead to varied biomarker profiles and treatment responses.
Future priorities include developing standardized diagnostic criteria and conducting biomarker-enriched, endotype-stratified trials for precision therapy.

Simplified

Heart failure with preserved ejection fraction (HFpEF) is responsible for approximately half of global heart failure cases and is characterized by marked symptom burden, frequent hospitalization and limited disease-modifying options. Its biology extends beyond the ventricle into vascular, myocardial, metabolic and inflammatory pathways that converge to produce diastolic dysfunction and systemic remodeling. Diagnostic inconsistency and frequent need for exertional testing to unmask elevated filling pressures underscore residual gaps in recognition and targeted therapy. This review synthesizes contemporary evidence spanning epidemiology, mechanisms, diagnostic strategies and phenotype-directed management. Therapeutic advances comprise sodium glucose cotransporter-2 (SGLT2) inhibitors as foundational disease-modifying therapy, Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as emerging adjunctive therapy for cardiometabolic HFpEF, structured exercise and lifestyle programs, hemodynamic-guided decongestion and ongoing evaluation of soluble guanylate cyclase (sGC) stimulators. Integrating these insights, HFpEF represents a family of endotypes unified by diastolic dysfunction but driven by distinct systemic mechanisms accounting for variable biomarker profiles and treatment responses. The priorities ahead center on linking human tissue biology with multi-omics and deep clinical phenotyping, standardization of diagnostic criteria, refinement of representative preclinical models and execution of biomarker-enriched, endotype-stratified trials to enable precision prevention and therapy in HFpEF.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PubMed

Heart failure with normal pumping strength: causes, diagnosis, and new treatment approaches

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief